Pregnancy, Breastfeeding, and More Linked to Lower CRC Risk Pregnancy, Breastfeeding, and More Linked to Lower CRC Risk
A new study shows that oral contraceptives, hormone replacement therapy, and pregnancy, among other factors, are associated with a decreased risk of developing colorectal cancer.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 11, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Gastrin-17 Predicts Oral Mucositis Severity in Head, Neck Cancer Gastrin-17 Predicts Oral Mucositis Severity in Head, Neck Cancer
A serum test can identify patients more likely to need early intervention. The study was published as a preprint and has not yet been peer reviewed.First Look (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - July 8, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Study: Decentralized and remote tech increases interest in clinical trial participation
More than 80% of cancer patients and survivors who responded to the survey were willing to use the majority of remote interventions, like oral medications delivered to the home, electronic informed consent and wearables. (Source: mobihealthnews)
Source: mobihealthnews - July 6, 2022 Category: Information Technology Source Type: news
Janssen Announces U.S. FDA Breakthrough Therapy Designation Granted for Talquetamab for the Treatment of Relapsed or Refractory Multiple Myeloma
June 29, 2022 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for talquetamab for the treatment of adult patients with relapsed or refractory multiple myeloma, who have previously received at least 4 prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody. Talquetamab is an investigational, off-the-shelf, T-cell redirecting bispecific antibody targeting both GPRC5D, a novel drug target, on multiple myeloma cells and CD3 o...
Source: Johnson and Johnson - June 29, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Receives Positive CHMP Opinion for IMBRUVICA ® (ibrutinib) in a Fixed-Duration Combination Regimen for Adult Patients with Previously Untreated Chronic Lymphocytic Leukaemia (CLL)
BEERSE, BELGIUM, June 24, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending approval of a new treatment option with IMBRUVICA® (ibrutinib) in an oral fixed-duration combination with venetoclax (I+V) for adults with previously untreated chronic lymphocytic leukaemia (CLL). Outcomes for patients with CLL have improved in the last decade with the advent of oral therapies that target the underlying disease biology.[1] This provides the opportunity...
Source: Johnson and Johnson - June 24, 2022 Category: Pharmaceuticals Source Type: news
Locusts can SMELL cancer: Scientists find insect's brains can detect three types of mouth cancer
Researchers at Michigan State University found locust's could tell the difference between three mouth cancers and non-cancerous cells. They said the technique was a 'very fast' alternative. (Source: the Mail online | Health)
Source: the Mail online | Health - June 22, 2022 Category: Consumer Health News Source Type: news
How Does Mouth Cancer Look Like?
Title: How Does Mouth Cancer Look Like?Category: Diseases and ConditionsCreated: 6/21/2022 12:00:00 AMLast Editorial Review: 6/21/2022 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - June 21, 2022 Category: Cancer & Oncology Source Type: news
How Can You Tell If a Mouth Sore Is Cancerous?
Title: How Can You Tell If a Mouth Sore Is Cancerous?Category: Diseases and ConditionsCreated: 6/21/2022 12:00:00 AMLast Editorial Review: 6/21/2022 12:00:00 AM (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - June 21, 2022 Category: Cancer & Oncology Source Type: news
Janssen Presents Updated Data at EHA for Teclistamab in Patients with Relapsed or Refractory Multiple Myeloma
June 10, 2022 (VIENNA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated efficacy and safety results from the teclistamab cohort of the Phase 1b TriMM-2 study (NCT04108195). Teclistamab, an investigational, off-the-shelf, T-cell redirecting bispecific antibody targeting B-cell maturation antigen (BCMA) is being studied in combination with DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj) in patients with relapsed or refractory multiple myeloma (RRMM) who have received three or more prior lines of therapy.1 Patients in the study, including a high proportion with prior anti-CD38 exposur...
Source: Johnson and Johnson - June 10, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
New IMBRUVICA ® (ibrutinib) Data in Fixed-Duration Combination Regimen Presented at EHA 2022 Shows Deep, Durable Response at Three Years in Untreated Chronic Lymphocytic Leukemia
June 10, 2022 (VIENNA) – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new and updated results from the Phase 2 CAPTIVATE study evaluating IMBRUVICA® (ibrutinib) in combination with venetoclax (I+V) as a potential fixed-duration (FD) treatment in adult patients with previously untreated chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Updated data from the FD cohort with three years of follow-up shows that I+V continues to demonstrate deep and durable responses and clinically meaningful progression-free survival (PFS) and overall survival (OS) in the first-line tre...
Source: Johnson and Johnson - June 10, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Janssen Presents Updated Results Evaluating First-in-Class GPRC5D Bispecific Antibody Talquetamab in Heavily Pretreated Patients with Multiple Myeloma
June 10, 2022 (VIENNA) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated results from the Phase 1 MonumenTAL-1 first-in-human dose-escalation study of talquetamab (NCT03399799), an investigational, off-the-shelf, T cell redirecting bispecific antibody targeting both GPRC5D, a novel multiple myeloma target, and CD3 on T cells.1 Results from the study showed encouraging responses in heavily pretreated patients with relapsed or refractory multiple myeloma (RRMM) who received talquetamab at the recommended subcutaneous Phase 2 dose (RP2D) administered weekly (QW) or every two weeks (Q2W).2 The...
Source: Johnson and Johnson - June 10, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
U.S. FDA approves Foundation Medicine ’s FoundationOne®CDx as a companion diagnostic for Roche’s Rozlytrek® (entrectinib)
FoundationOneCDx can now be used to identify patients with ROS1 fusion-positive non-small cell lung cancer or patients with NTRK fusion-positive solidtumours for whom treatment withRozlytrek may be appropriateThis approval marks the first and only companion diagnostic indication forRozlytrek, and another important milestone intumour-agnostic approaches for people living with rare cancersRoche is a leader in drivingpersonalised healthcare around the world through validated diagnostic tools, genomic insights and a continued focus on drug developmentBasel, 9 June 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that ...
Source: Roche Media News - June 9, 2022 Category: Pharmaceuticals Source Type: news
Janssen Presents Initial Results from the Phase 2 RAGNAR Study of BALVERSA ® (erdafitinib) in Patients with Advanced Solid Tumors with FGFR Alterations
CHICAGO, ILLINOIS, June 7, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced initial results from the pivotal Phase 2 RAGNAR study evaluating the investigational use of BALVERSA® (erdafitinib), a fibroblast growth factor receptor (FGFR) kinase inhibitor, in patients with advanced solid tumors with prespecified FGFR alterations. At a planned interim analysis (IA), responses were observed across a variety of FGFR-driven solid tumors for patients who had exhausted standard treatment options prior to being treated with BALVERSA®.[1] These results will be featured in an oral presentation (...
Source: Johnson and Johnson - June 7, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Novel Agent Lessens Mucositis in Head and Neck Cancers
(MedPage Today) -- CHICAGO – Severe oral mucositis among patients undergoing radiation and platinum-based chemotherapy for locally-advanced head and neck cancers can be significantly reduced by the novel agent avasopasem manganese, researchers... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - June 6, 2022 Category: Hematology Source Type: news
Updated Data for Janssen ’s Bispecific Teclistamab Suggest Continued Deep and Durable Responses in the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
CHICAGO, ILLINOIS, June 5, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced updated efficacy and safety results from the teclistamab Phase 1/2 MajesTEC-1 study. Teclistamab is an investigational, off-the-shelf, T-cell redirecting bispecific antibody targeting B-cell maturation antigen (BCMA), which is being studied in patients with relapsed or refractory multiple myeloma (RRMM) who have received three or more prior lines of therapy.1 The data were featured as part of an oral session during the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Additional poster presentations f...
Source: Johnson and Johnson - June 5, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
